The New Gold Standard of Drug Commercialization 

Sell, out-license or launch internally: These are the three traditional options to commercialize a pharmaceutical product. Selling and out-licensing are common, but cause innovators to lose ownership in an investment that takes years to develop. Launching internally requires an average investment of $125MM+ before the product even hits the shelves. Until now, there was no other way to take a product to market.

In a CEO panel moderated by EVERSANA’s Greg Skalicky and Jim Lang, EVOKE CEO Dave Gonyer and Zosano CEO Steven Lo explain how selecting EVERSANA as their commercialization partner allows them to maintain full ownership of their asset while minimizing upfront risk. Watch the video

Download Greg Skalicky's latest article to learn how our complete end-to-end commercialization model enables manufacturers to bring their drug to market at a fraction of the cost of “going it alone” or partnering with another pharmaceutical company. The new model offers manufacturers the ability to:

  • Maintain full ownership of their asset.
  • ​Capture full revenue potential through maturity.
  • Optimize their launch performance.


Field will not be visible to web visitor

Copyright 2020 Industry Dive Privacy Policy | Terms of Use